Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 6, 2012, Pages

  Gaykema, Sietske B M ^a   Brouwers, Adrienne H ^a   Hovenga, Sjoerd ^b   Lub de Hooge, Marjolijn N ^a   De Vries, Elizabeth G E ^a   Schröder, Caroline P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NIJ SMELLINGHE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LEUPRORELIN; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ZIRCONIUM 89; ZIRCONIUM DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SIZE; CASE REPORT; HISTOLOGY; HUMAN; LIVER BIOPSY; LYMPH NODE DISSECTION; MALE; MASTECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SACRUM; SPINAL NEOPLASMS;

EID: 84857565599     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.0204     Document Type: Article

References (22)

1. Dijkers EC, Oude Munnink TH, Kosterink JG, et al: Biodistribution of Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:586-592, 2010
2. Cardoso F, Senkus-Konefka E, Fallowfield L, et al: Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v15-19, 2010 (suppl 5)
3. NCCN clinical practice guidelines in clinical oncology. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp
4. Tanchiu E, Kaufman PA, Paik S, et al: registHER: A prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer. J Clin Oncol 23:44s, 2005 (abstr 670)
5. Masood S, Bui MM: Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study. Ann Clin Lab Sci 30:259-265, 2000 (Pubitemid 30620800)
6. Shimizu C, Fukutomi T, Tsuda H, et al: c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 73:17-20, 2000 (Pubitemid 30067528)
7. Tanner M, Järvinen P, Isola J: Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 61:5345-5348, 2001 (Pubitemid 32694907)
8. Gancberg D, Di Leo A, Cardoso F, et al: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13:1036-1043, 2002
9. Vincent-Salomon A, Jouve M, Genin P, et al: HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 94:2169-2173, 2002 (Pubitemid 34411973)
10. Edgerton SM, Moore D 2nd, Merkel D, et al: erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 11:214-221, 2003 (Pubitemid 37082057)
11. Regitnig P, Schippinger W, Lindbauer M, et al: Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203:918-926, 2004 (Pubitemid 39089280)
12. Zidan J, Dashkovsky I, Stayerman C, et al: Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93:552-556, 2005 (Pubitemid 43079998)
13. Gong Y, Booser DJ, Sneige N: Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103:1763-1769, 2005 (Pubitemid 40563246)
14. Vincent-Salomon A, Pierga JY, Couturier J, et al: HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: A possible tool for anti-HER2 therapy management? Br J Cancer 96:654-659, 2007
15. Santinelli A, Pisa E, Stramazzotti D, et al: HER-2 status discrepancy between primary breast cancer and metastatic sites. impact on target therapy. Int J Cancer 122:999-1004, 2008 (Pubitemid 351213996)
16. Lower EE, Glass E, Blau R, et al: HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113:301-306, 2009
17. Kollias J, Pinder SE, Denley HE, et al: Phenotypic similarities in bilateral breast cancer. Breast Cancer Res Treat 85:255-261, 2004 (Pubitemid 38987260)
18. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
19. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
20. Perik PJ, Lub-De Hooge MN, Gietema JA, et al: Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24:2276-2282, 2006 (Pubitemid 46630657)
21. Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838, 1994 (Pubitemid 24194147)
22. Hudziak RM, Lewis GD, Winget M, et al: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165-1172, 1989 (Pubitemid 19071685)